ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0759

Derivation and Validation of Four Patient Clusters in Still’s Disease, Results from GIRRCS AOSD-study Group and AIDA Network Still Disease Registry
Abstract Number: 0760

Treatment Patterns and Outcomes in Patients with Macrophage Activation Syndrome Secondary to Still’s Disease Treated with Emapalumab: The REAL-HLH Study
Abstract Number: 0761

EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still’s Disease (AOSD)
Abstract Number: 0762

Liver Disease Is a Common Feature of HA20 That Causes Significant Morbidity Associated with Interferon Induction
Abstract Number: 0763

Sticking the Landing: A 3-Year Qualitative Longitudinal Study on Navigating Transitions in Pediatric Rheumatology Fellowship
Abstract Number: 0764

An Atypical ClassRheum: RheumMadness, a Collaborative Rheumatology Competition Building Knowledge and Community
Abstract Number: 0765

RheumMadness and TheMednet: The Impact of a Collaboration Between Independent Educational Initiatives
Abstract Number: 0766

The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis
Abstract Number: 0767

Current Musculoskeletal Ultrasound Practices of 12 Years of past Participants of a 10-Months Rheumatology Ultrasound Training Program (Ultrasound School of North American Rheumatologists)
Abstract Number: 0768

Using Participatory Design-Thinking Process to Create a More Applicant-Centered Rheumatology Fellowship Interview Experience
Abstract Number: 0769

Development and Validation of a Combined Clinical and Genetic Risk Score for Interstitial Lung Disease in a Large, Multicenter, Prospective Rheumatoid Arthritis Cohort
Abstract Number: 0770

Plasma Matrix Metalloproteinases in Rheumatoid Arthritis-Interstitial Lung Disease: Associations with Disease Presence, Severity, and Subtypes
Abstract Number: 0771

A Modified Idiopathic Pulmonary Fibrosis-Derived Composite Biomarker Score Is Associated with Interstitial Lung Disease Among U.S. Veterans with Rheumatoid Arthritis
Abstract Number: 0772

MUC5B Promoter Variant and Survival in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 0773

Sputum Lautropia Abundance Is Decreased in Rheumatoid Arthritis-Associated Pulmonary Fibrosis and Correlates with Lung Disease Severity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].